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CLINICAL UPDATE
Cardiovascular risk prevention in peripheral artery
disease
Daniel G. Hackam, BSc, MD, FRCPC, Toronto, Ontario, Canada
Patients with peripheral arterial disease are at greatly elevated risk for stroke and myocardial infarction and are six times
more likely to die from cardiovascular causes than those without the disease. The available evidence supports the provision
of an antiplatelet agent, a statin, and an angiotensin-converting enzyme inhibitor for cardiovascular protection in these
patients. When used together, these approaches are expected to produce a cumulative relative risk reduction of
approximately 80%. Given the high baseline risk of this population and the effectiveness of these interventions, a
combination of multiple drug therapies, in concert with aggressive lifestyle change and revascularization (where
appropriate), can substantially reduce the burden of morbidity and mortality in patients with peripheral arterial disease.
(J Vasc Surg 2005;41:1070-3.)Peripheral arterial disease (PAD) is a highly prevalent
condition. In North America and Western Europe alone,
an estimated 27 million people are affected by PAD.1
Patients with PAD are at markedly elevated risk of myocar-
dial infarction and stroke, and are six times more likely to
die within 10 years than patients without PAD.2 Patients
with symptomatic, advanced peripheral vascular disease
have a particularly poor long-term prognosis, with a 15-
fold increased mortality at 10 years.2 The systemic nature of
atherosclerosis within the individual mandates a global,
risk-factor driven, comprehensive approach to cardiovascu-
lar prevention in every patient affected by PAD. In recent
years, a number of therapeutic strategies for secondary
prevention traditionally used in patients with cerebrovascu-
lar or coronary artery disease have been validated specifi-
cally in the PAD population. This report outlines pharma-
cologic approaches for vascular risk reduction, including
the evidence underpinning these therapies.
ANTIPLATELET AGENTS
Aspirin. The Antithrombotic Trialists Collaboration’s
recent overview summarized data from 9,214 patients with
PAD enrolled in 42 trials.3 Overall, the use of antiplatelet
therapy (primarily aspirin) provided a risk reduction of 23%
(P  .004) for the composite of cardiovascular death,
myocardial infarction, or stroke in this population. A recent
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1070Cochrane overview also showed a benefit of aspirin on the
local circulation of revascularized PAD patients, with a 41%
reduction (95% confidence interval [CI], 21 to 55) in the
risk of graft occlusion after 12 months of therapy.4
The Antithrombotic Trialists’ overview suggested that
an aspirin dose of 80 to 325mg/day was at least as effective
as higher doses; higher doses of aspirin are also associated
with greater risks of gastrointestinal toxicity and bleeding.
Recent post hoc analyses of two large, prospective, ran-
domized trials suggested that the dose of aspirin that best
balances safety and efficacy in patients with vascular disease
is 75 mg to 100 mg/day.5,6
Thienopyridine agents. Thienopyridine agents are
also of benefit in patients with PAD. In the Clopidogrel
versus Aspirin in Patients at Risk of Ischemic Events (CA-
PRIE) trial, 19,185 patients with a history of atheroscle-
rotic vascular disease were randomly allocated to daily doses
of clopidogrel (75 mg) or aspirin (325 mg), including a
large subgroup of patients with established PAD (n 
6,452).7 Intriguingly, the PAD subgroup appeared to ben-
efit most from clopidogrel, with a relative risk reduction of
23.8% (95% CI, 8.9 to 36.2), approximately three times
greater than the overall trial reduction of 8.7%; the test for
heterogeneity by patient subgroup for this effect was sig-
nificant (P  .042).
A recent economic study modelled on the CAPRIE
dataset suggests that the use of clopidogrel is cost-effective
in patients with PAD and provides a significant gain in
quality-adjusted life expectancy.8 The combination of clo-
pidogrel and aspirin therapy appears to provide significantly
greater platelet inhibition than monotherapy alone; al-
though this strategy has been evaluated in patients with a
history of coronary artery disease or stroke, trials with hard
clinical end-points in patients with PAD have yet to be
completed.9
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The incomplete protection afforded by antiplatelet
agents in the setting of PAD has provided considerable
impetus to the study of anticoagulant therapy in this pop-
ulation. A recent meta-analysis found that the use of cou-
marin anticoagulants after infrainguinal bypass surgery re-
duced the risk of bypass graft failure (odds ratio [OR],
0.43; 95% CI, 0.26 to 0.73) and limb loss (OR, 0.34; 95%
CI, 0.17 to 0.70) and showed a trend towards decreased
mortality (OR, 0.66; 95% CI, 0.38 to 1.15).10 The greatest
effect on maintaining graft patency was found in patients
with venous grafts, which was supported by other trial data
comparing coumarin therapy with antiplatelets (aspirin or
aspirin-dipyridamole). Another meta-analysis also found
significant reductions in graft occlusion and mortality with
antithrombotic therapy, although this review pooled trials
of antiplatelet and anticoagulant therapy.11
These benefits must be balanced against the increased
risk of bleeding complications in patients treated with
anticoagulants. Currently, a large randomized trial enroll-
ing patients with PAD is comparing the relative effective-
ness of combined warfarin and antiplatelet therapy with
antiplatelet therapy alone in reducing cardiovascular events;
the results of this study should add clarity to the question of
oral anticoagulation among patients with PAD.12
STATINS
Strong evidence in support of cholesterol lowering with
statins in the setting of PAD was recently reported.13 The
Heart Protection Study enrolled 20,536 patients with vas-
cular disease or diabetes mellitus, randomly allocating them
to treatment with simvastatin (40 mg daily) or placebo for
a mean follow-up of 5 years. The trial included 6,748
patients with PAD (33% of the study population). These
patients had the highest placebo event rate of the four main
inclusion groups in the study (32.7% after 5 years) com-
pared with patients with cerebrovascular disease (29.8%),
Guidance for the initiation and monitoring of statins in pa
Recommendation 1: Agents
High potency statins, such as simvastatin and atorvastatin, have th
Less potent agents, such as pravastatin or lovastatin, may be inferio
Recommendation 2: Dosage and titration
Usual starting doses: simvastatin 20 mg once daily, atorvastatin 10
Current guidelines recommend a low-density lipoprotein choleste
mg/dL favored in patients at very high risk. This category inclu
diabetes), poorly controlled risk factors (esp. continued cigarett
syndromes).21
Recommendation 3: Monitoring
Baseline measurements include a lipid profile, creatine kinase, alan
ALT/AST should be repeated 12 weeks after starting therapy, t
symptoms to their physician immediately.
Recommendations 4: Major cautions
Statins should not be used in patients with chronic or active liver
or cytochrome P-450 3A4 inhibitors. Caution should also be ex
multisystem diseases, chronic renal insufficiency (especially duecoronary artery disease (27.5%), or diabetes mellitus(25.1%). In the PAD group, treatment with simvastatin
provided a highly significant 24% relative reduction and a
6.3% absolute reduction in the risk of major vascular events.
Notably in the overall trial, the subgroup of patients
with a baseline low-density lipoprotein cholesterol
(LDL-C) level 2.6 mmol/L (n  3,421) experienced
virtually the same absolute and relative risk reductions as
the 17,115 patients whose starting LDL-C was 2.6
mmol/L.
Randomized trials also suggest improvements in walk-
ing performance in patients with PAD treated with st-
atins.14,15 Recommended agents, starting doses, and labo-
ratory monitoring are provided in the Table.
ANGIOTENSIN-CONVERTING ENZYME
INHIBITORS
The Heart Outcomes Prevention Evaluation (HOPE)
study randomized patients with vascular disease or diabetes
mellitus plus one additional risk factor to treatment with
ramipril (10 mg/day) or placebo. The HOPE trialists
recently published the results of an analysis of patients with
PAD enrolled in the trial.23 Of the 9,541 patients random-
ized, 1,715 had symptomatic PAD and 2,118 had asymp-
tomatic PAD (defined as an ankle/brachial index 0.9 in
the absence of symptoms). In patients with symptomatic
PAD, ramipril reduced the risk of a cardiovascular event in
follow-up by 25%, with a number needed to treat to prevent
one event of 18 (with 4.5 years of treatment). Moreover,
patients with asymptomatic PAD also benefited substan-
tially from treatment with ramipril (absolute risk reduction
5.9%, number needed to treat 17).
Of further note, the mean blood pressure at entry in
patients with clinical or silent PAD was 143/79 mm Hg,
implying that ramipril is likely to benefit many PAD pa-
tients with borderline or normal blood pressure. Indeed,
the comparison of HOPE with previous hypertension trials
appears to demonstrate a blood pressure-independent ef-
s with peripheral arterial disease
est evidence base in patients with peripheral arterial disease.14,16-18
hese drugs.19,20
once daily.
eatment goal of 100 mg/dL, with an optional goal of 70
stablished vascular disease plus multiple major risk factors (esp.
king), the metabolic syndrome, or patients with acute coronary
minotransferase (ALT), and aspartate aminotransferase (AST).
nnually.22 Patients should be instructed to report muscle
e and should be used with caution in patients receiving fibrates
ed in the presence of risk factors for myopathy, including
betes mellitus), small body frame/frailty, or alcohol abuse.tient
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to diafect of ramipril on cardiovascular outcomes.24 In patients
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lowering strategy also appears to be highly effective for
preventing cardiovascular events.25
LIFESTYLE MODIFICATION
Smoking cessation and structured exercise are vital
components of the treatment plan of patients with PAD
and should not be superseded by pharmacologic treat-
ments. For patients who smoke, successful cessation is
probably more effective at preventing cardiovascular
morbidity and mortality than any drug therapy.26,27
Cessation also prevents progression of the disease in
smokers and improves graft patency in revascularized
patients.28,29
Systematic reviews have also shown that exercise
significantly improves total walking distance by 179 m
(95% CI, 60 to 298 m) and maximal exercise time by 6.5
minutes (95% CI 4.4 to 8.7 minutes).30,31 These effects
were superior to those of angioplasty or antiplatelet
therapy and were equivalent to that of surgical interven-
tion. Moreover, supervised exercise improves quality of
life, cardiovascular risk factors, endothelial function, and
hemorheologic markers.32,33
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With the above article, we introduce a new section of the Journal, termed “Clinical Update.” Articles
in this section are intended to be concise, current reviews of clinical topics that will impact patient care.We
will request specific reviews on important topics but also now invite submission of such articles for peer
review and potential publication. Interested authors should contact the Editors to determine if a particular
topic would be of interest and is not already under review. Articles should be no longer than 3000 words,
should have a limited, but useful reference list, and comprise no more than 15 manuscript pages, double
spaced, including tables. They should be submitted using the Editorial Manager system under the article
type “Clinical Update.” Our intention is to provide short, relevant clinical reviews on important topics
regarding vascular disease.
